Clinical trial · Observational
Asian Myeloproliferative Neoplasm (MPN) Registry
Asian Myeloproliferative Neoplasm (MPN) Registry - An Asian Myeloid Working Group (AMWG) Project.
NCT05882773CI-TRIAL-00066800recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Essential Thrombocythemia | Essential Thrombocythemia | ONTOLOGY_EXACT | 0.98 |
| Myeloproliferative Neoplasm | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
| Polycythemia Vera | Polycythemia Vera | ONTOLOGY_EXACT | 0.98 |
| Post-essential Thrombocythemia Myelofibrosis | — | UNRESOLVED | — |
| Post-polycythemia Vera Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | ALIAS | 0.90 |
| Primary Myelofibrosis | Primary Myelofibrosis | ONTOLOGY_EXACT | 0.98 |
| Primary Myelofibrosis, Fibrotic Stage | Overt Primary Myelofibrosis | ALIAS | 0.90 |
| Primary Myelofibrosis, Prefibrotic Stage | Prefibrotic Primary Myelofibrosis | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Time to progression to secondary myelofibrosis (for PV and ET)
- timeFrame
- 10 years
- description
- Measured in months, from date of diagnosis of MPN to date of documentation of secondary myelofibrosis (event), death (event) or latest follow-up (censor). Patient without an event will be censored at date last known to be progression-free
- measure
- Progression-free survival (PFS)
- timeFrame
- 10 years
- description
- Measured in months, from date of diagnosis of MPN to the date of the first MDS or AML or death due to any cause. Patient without an event will be censored at date last known to be progression-free and alive.
- measure
- Overall survival (OS)
- timeFrame
- 10 years
- description
- Measured in months from the date of diagnosis of MDS until the date of death due to any cause. Patient who is alive will be censored at the date last known alive
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years old at the time of diagnosis of MPN. 2. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification): 1. Polycythaemia vera 2. Essential thrombocythemia 3. Primary myelofibrosis, pre-fibrotic/early stage 4. Primary myelofibrosis, overt fibrotic stage 5. Post-polycythaemia vera myelofibrosis 6. Post-essential thrombocythaemia myelofibrosis 7. MPN-unclassifiable 3. All subjects need to provide informed consent. Exclusion Criteria: A subject will not be eligible if he/she meets any of the following criteria: 1\. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification
References
Publications (0)
Data not yet available
No reference posted for this study.